Yüklüyor......

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology

BACKGROUND: Incremental cost-effectiveness ratios (ICERs) are used to assess the value for money of new drugs. Many believe that ICERs for drugs that treat rare diseases are much higher than those of common drugs. Our objective was to compare the proportion of ICERs that are cost effective for rare...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacoecon Open
Asıl Yazarlar: Jayasundara, Kavisha, Krahn, Murray, Mamdani, Muhammad, Hoch, Jeffrey S., Grootendorst, Paul
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2017
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691840/
https://ncbi.nlm.nih.gov/pubmed/29441496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-017-0022-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!